Biogen's treatment for neurodegenerative disorder spinal muscular atrophy (SMA) Spinraza has come under pressure in an increasingly competitive market, but the company hopes a new high-dose ...

In a report released today, David Amsellem from Piper Sandler maintained a Hold rating on Biogen (BIIB – Research Report), with a price target ...

Exchange Traded Concepts LLC lifted its stake in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 37.5% during the 4th ...

Fifth Third Bancorp reduced its stake in Biogen Inc. (NASDAQ:BIIB – Free Report) by 3.4% in the fourth quarter, HoldingsChannel reports. The fund owned 3,246 shares of the biotechnology company’s ...

Last week, the FDA and EMA have accepted Biogen's regulatory filings seeking label expansion for a higher dose of its blockbuster spinal muscular atrophy (SMA) drug Spinraza. This new proposed ...

Spinal muscular atrophy (SMA) therapy Spinraza has been a key earner for Biogen in recent years, but with sales now heading into reverse, the company is looking to extend its franchise.

Learn more about whether Catalyst Pharmaceuticals, Inc. or Ionis Pharmaceuticals, Inc. is a better investment based on AAII's ...

A Boston-area biopharmaceutical firm has submitted a biologics license application to the FDA for its investigational, fully ...

The high-dose Spinraza is Biogen's answer to competitors such as Novartis' gene therapy Zolgensma. Specifically, the combo is approved in Europe for patients with epidermal growth factor receptor ...